Bristlecone Advisors, LLC Neurocrine Biosciences Inc Transaction History
Bristlecone Advisors, LLC
- $1.17 Billion
- Q2 2024
A detailed history of Bristlecone Advisors, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bristlecone Advisors, LLC holds 2,885 shares of NBIX stock, worth $328,890. This represents 0.03% of its overall portfolio holdings.
Number of Shares
2,885
Previous 2,980
3.19%
Holding current value
$328,890
Previous $411,000
3.41%
% of portfolio
0.03%
Previous 0.04%
Shares
13 transactions
Others Institutions Holding NBIX
# of Institutions
640Shares Held
95.2MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$525 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$281 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$269 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...